Prevision Medicine, a Swiss-based company and leader in functional precision oncology, has announced the clinical launch of its AML Drug Screening Test, powered by the company’s proprietary PrevisionOne platform. The test, which is research use only, is designed to help oncologists rapidly identify the most effective therapies for patients with acute myeloid leukemia (AML).
AML is one of the most aggressive and heterogeneous forms of blood cancer. Because of its rapid progression, treatment often needs to begin within just a few days. Prevision Medicine’s AML Drug Screening Test enables clinicians to make more informed, patient-specific treatment decisions by evaluating patient-derived malignant and non-malignant cells against more than 100 drugs and drug combinations, only requiring small samples of blood or bone marrow.
The AML Drug Screening Test is based on evidence collected through two previous interventional clinical trials – EXALT-1 and DARTT-1 – showing significant clinical benefit for patients. The DARTT-1 interventional study demonstrated a positive Overall Survival (OS) ratio of 3.4 for patients receiving the top recommended therapies based on the screening. This means that, on average, these patients lived more than three times as long as
those receiving fewer recommended therapies.
Prevision Medicine’s AML Drug Screening Test is built on collaborations with several hospitals across Switzerland, Germany, and Austria, and draws on knowledge from 300+ AML patient samples. In the DARTT-1 clinical trial, the test achieved a 100% success rate in generating actionable clinical insights, meaning that every patient sample tested yielded results that could directly guide treatment decisions.
“AML presents a critical need for precision-guided treatment strategies, given its complexity and the urgency of care. PrevisionOne’s high-throughput drug screening platform provides oncologists with the clinical clarity they need to identify effective therapies quickly – evidence-backed insights that have already translated into improved patient survival in clinical studies,” said Dr. Philip Zimmermann, CEO of Prevision Medicine.
Prevision Medicine is an ETH Zurich spinoff at the forefront of functional precision medicine, dedicated to reshaping cancer care through advanced, evidence-driven drug screening technologies. Its proprietary PrevisionOne platform delivers actionable insights to support data-driven, patient-specific treatment strategies across multiple cancer types, improving outcomes and quality of care.
